Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 14, 2026Current Pharmaceutical Design

Efficacy and Safety of Finerenone for Renal and Cardiovascular Events in DiabeticKidney Disease: A Meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does finerenone reduce renal and cardiovascular events in patients with diabetic kidney disease?

Population

15,527 patients with diabetic kidney disease (DKD) pooled from 7 randomized controlled trials

Comparison

Finerenone vs Control

Design

Meta-analysis

Authors

WCWenmin ChenLZLingqian ZhengYLYongda Lin

Discussion

Loading...

Member takes

Overview

Finerenone provides significant renal and cardiovascular benefits, including reduced heart failure hospitalization and kidney disease progression, in patients with diabetic kidney disease, though it increases the risk of hyperkalemia.

Key Points

  • This research aims to evaluate the efficacy and safety of finerenone in treating diabetic kidney disease (DKD).
  • Conducted a meta-analysis of randomized controlled trials (RCTs) involving finerenone and DKD
  • Searched multiple databases including PubMed and Embase for relevant RCTs
  • Assessed risk of bias and publication bias using established tools
  • Finerenone significantly reduced urinary albumin-to-creatinine ratio from baseline (p < 0.00001)
  • Showed a significant reduction in the risk of a ≥40% decline in eGFR (p < 0.0001)
  • Reduced hospitalization for heart failure (p = 0.004) compared to controls
  • Comparable rates of total adverse events, but higher incidences of hyperkalemia noted

Structured PICO

Does finerenone reduce renal and cardiovascular events in patients with diabetic kidney disease?

P
Population
15,527 patients with diabetic kidney disease (DKD) pooled from 7 randomized controlled trials
I
Intervention
Finerenone
C
Comparator
Control
O
Outcome
Renal and cardiovascular events (including urinary albumin-to-creatinine ratio, eGFR decline, progression to end-stage kidney disease, composite cardiac outcomes, and hospitalization for heart failure)composite

Finerenone provides significant renal and cardiovascular benefits, including reduced heart failure hospitalization and kidney disease progression, in patients with diabetic kidney disease, though it increases the risk of hyperkalemia.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/69ddd99ae195c95cdefd6dbbhttps://doi.org/10.2174/0113816128433708251128041537
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Finerenone Versus Placebo on Renal Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review and Meta-Analysis2025 · 2 citations
  2. 2Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF2025
  3. 3A systematic review and meta-analysis on the efficacy and safety of finerenone in the progression of heart failure2025
  4. 4Real-world outcomes of Finerenone in patients with diabetic kidney disease in Saudi Arabia2026
  5. 5Effect of Finerenone on Morbidity and Mortality in CKD.2025 · 6 citations